Molecular characterization of acute myeloid leukemia

Haematologica

Volumn 93, Issue 7, 2008, Pages 976-982

  Döhner, Konstanze ^a   Döhner, Hartmut ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Acute myeloid leukemia somatic mutation; CEBPA; Chromosomal abnormality; FLT3; NPM1

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CCAAT ENHANCER BINDING PROTEIN ALPHA; CD135 ANTIGEN; CORE BINDING FACTOR; DEPSIPEPTIDE; LESTAURTINIB; MIDOSTAURIN; MIXED LINEAGE LEUKEMIA PROTEIN; NUCLEOPHOSMIN; NUCLEOPHOSMIN 1; SORAFENIB; SUNITINIB; TRANSCRIPTION FACTOR RUNX1; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; CYTOGENETICS; DRUG ACTIVITY; EDITORIAL; FUSION GENE; HUMAN; KARYOTYPE; LEUKEMOGENESIS; NONHUMAN; NONSENSE MUTATION; POINT MUTATION; PROGNOSIS; SOMATIC MUTATION;

CCAAT-ENHANCER-BINDING PROTEINS; CHROMOSOME ABERRATIONS; CYTOGENETICS; FMS-LIKE TYROSINE KINASE 3; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MUTATION; NUCLEAR PROTEINS; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; TRANSLOCATION, GENETIC;

EID: 46849122024     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.13345     Document Type: Editorial

References (24)

1. Fröhling S, Scholl C, Gilliland DG, Levine RL. Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol 2005;23:6285-95.
2. Mrózek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev 2004;18:115-36.
3. Estey E, Döhner H. Acute myeloid leukaemia: Lancet 2006; 368:1894-907.
4. Mrózek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 2007;109:431-48.
5. Döhner H. Implication of the molecular characterization of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2007;2007:412-9.
6. Kelly LM, Gilliland DG. Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet 2002;3:179-98.
7. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, et al. Gimema Acute Leukemia Working Party. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352:254-66.
8. Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008;358:1909-18.
9. Whitman SP, Archer KJ, Feng L, Baldus C, Becknell B, Carlson BD, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res 2001;61:7233-9.
10. Thiede C, Steudel C, Mohr B, Schaich M, Schäkel U, Platzbecker U, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002;99:4326-35.
11. Wouters BJ, Alberich Jordà M, Keeshan K, Louwers I, Erpelinck-Verschueren CAJ, Tielemans D, et al. Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. Blood 2007;110:3706-14.
12. Whitman SP, Liu S, Vukosavljevic T, Rush LJ, Yu L, Liu C, et al. The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy. Blood 2005;106:345-52.
13. King-Underwood L, Renshaw J, Pritchard-Jones K. Mutations in the Wilms' tumor gene WT1 in leukemias. Blood 1996;87:2171-9.
14. Summers K, Stevens J, Kakkas I, Smith M, Smith LL, Macdougall F, et al. Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML. Leukemia 2007;21:550-1.
15. Schnittger S, Dicker F, Kern W, Haferlach T, Haferlach C. Cooperating molecular mutations in AML/RUNX1 mutated AML differ dependent on the cytogenetic subgroup. Blood 2007;110:114a (abstr).
16. Schnittger S, Kohl TM, Haferlach T, Kern W, Hiddemann W, Spiekermann K, et al. KIT-D816 mutations in AML1-ETO positive AML are associated with impaired event-free and overall survival. Blood 2006;107:1791-9.
17. Paschka P, Marcucci G, Ruppert AS, Mrózek K, Chen H, Kittles RA, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 2006;24:3904-11.
18. Thiede C, Bloomfield CD, Lo Coco F, Fröhling S, Hiddemann W, Krauter J, et al. The high prevalence of FLT3-ITD mutations is associated with the poor outcome in adult patients with t(6;9)(p23;q34) positive AML - Results of an international metaanalysis. Blood 2007; 110:234a (abstr).
19. Lugthart S, van Drunen E, van Norden Y, van Hoven A, Erpelinck CAJ, Valk PJM, et al. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood 2008;111:4329-37.
20. Corbacioglu A, Fröhling S, Paschka P, Marcucci G, Anhalt A, Urlbauer K, et al. Acute myeloid leukemia (AML) with 9q aberrations occurring within a non-complex karyotype is highly associated with CEBPA and NPM1 mutations - a joint analysis of the German-Austrian AML Study Group (AMLSG) and Cancer and Leukemia Group B (CALGB). Blood 2007;110:234a (abstr).
21. Mrózek K. Acute myeloid leukemia with complex karyotype. Sem Oncol 2008, in press.
22. Rücker FG, Bullinger L, Schwaenen C, Lipka DB, Wessendorf S, Fröhling S, et al. Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. J Clin Oncol 2006;24:3887-94.
23. Schoch C, Haferlach T, Bursch S, Gerstner D, Schnittger S, Dugas M, et al. Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: a detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24-color FISH. Genes Chromosomes Cancer 2002;35:20-9.
24. Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili N, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008;451:335-9.